Technology & Products
PDL’s antibody humanization technology and patents are among the most successful and profitable in the biotechnology industry. At its foundation is PDL’s intellectual property platform consisting of the Queen et al. patents, which have been widely validated commercially and have generated significant royalties from some of the leading biotechnology and pharmaceutical companies in the industry. Currently PDL receives royalties on a number of marketed products that use its technology and PDL has licensed a number of humanized antibody products in late stage clinical trials.
Antibodies are an increasingly important tool in the arsenal of advanced “targeted therapies” that biotechnology and pharmaceutical companies are rolling out to combat diseases such as cancer. Traditional cancer drugs kill cancer cells as well as healthy, making them toxic and limiting the doses that can be given to patients. Targeted therapies, however, impact only cancer cells and are often more effective than traditional chemotherapy regimens.
Companies currently holding patent licenses for commercialized products include:
Herceptin® (trastuzumab), Xolair® (omalizumab), Avastin® (bevacizumab), Perjeta™ (pertuzumab), Lucentis® (ranibizumab injection), KadcylaTM (ado-trastuzumab emtansime), and GazyvaTM (obinutuzumab injection)